Endo Presents Data on the Use of a Standing MRI for the Evaluation of Cellulite at the American Society for Dermatologic Surgery (ASDS) Annual Meeting
The first abstract poster will be titled "The First Reported Use of Standing MRI for the Evaluation of Cellulite: A Case Study Comparison of Standing vs. Standard (Prone) MRI." This case study was designed to compare the anatomy of collagen septae in a woman with cellulite using a standing MRI versus standard (prone) MRI, because cellulite is typically observed in an upright/standing position. Such comparison results showed a <10° difference between the angle of collagen septae orientation relative to the dermis in the standing and prone MRI. Septae orientation in the prone position was not perpendicular to the skin.
The second abstract poster, titled "Two Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Collagenase Clostridium Histolyticum (CCH) for the Treatment of Cellulite," includes data previously presented at the 2019
"We are pleased that the data from these studies will be presented at the premier meeting for dermatologic surgeons," said Matthew Davis, M.D., R.Ph., Chief Medical Officer, Senior Vice President, Research and Development, Branded Pharmaceuticals at Endo Pharmaceuticals. "It is important that aesthetic healthcare providers have data on the most effective ways to evaluate the internal structure of cellulite. We believe our continued research will improve potential outcomes and patient satisfaction with cellulite treatments that target collagen septae."
About Cellulite
Cellulite is a localized alteration in the contour of the skin that has been reported in 85 to 98 percent of post-pubertal females and affects women of all races and ethnicities.1,2 The primary cause of the condition is a thickening of the collagen septae that attach the skin to the underlying fascia layers with additional contributing protrusions of subcutaneous fat. The septae tether the skin, which causes the surface dimpling characteristic of cellulite.2,3 Cellulite clinically presents on the buttocks, thighs, lower abdomen and arms.
It is known that cellulite is different from generalized obesity. In generalized obesity, adipocytes undergo hypertrophy and hyperplasia that are not limited to the pelvis, thighs, and abdomen.4 In areas of cellulite, characteristic large, metabolically stable adipocytes have physiologic and biochemical properties that differ from adipose tissue located elsewhere. Weight gain makes cellulite more noticeable, but it may be present even in thin subjects. Genetics may also play a role, since cellulite tends to run in families.
Despite multiple therapeutic approaches for the attempted treatment of patients with cellulite, there are currently no
About
About the
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation, including, but not limited to, the statements by Dr. Davis, and other statements regarding research and development outcomes, efficacy, adverse reactions, market and product potential and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect
References
- Avram M. Cellulite: a review of its physiology and treatment,
Journal of Cosmetic Laser Therapy 2004; 6: 181–185. - Khan MH et al. Treatment of cellulite: Part I. Pathophysiology. J Am Acad Dermatol. 2010 Mar;62(3):361-70.
- Querleux B et al. Anatomy and physiology of subcutaneous adipose tissue by in vivo MRI and spectroscopy: Relationship with sex and presence of cellulite,
Skin Research and Technology; 8: 118-124. - Khan MH, Victor F, Rao B, Sadick NS. Treatment of cellulite: Part I. Pathophysiology. J Am Acad Dermatol 2010;62(3):361-370.
- Zerini I et al. Cellulite treatment: a comprehensive literature review. J Cosmet Dermatol. 2015 Sep 14(3):224-40
SOURCE
Media: Heather Zoumas-Lubeski, (484) 216-6829, media.relations@endo.com; Investors: Pravesh Khandelwal, (845) 364-4833, relations.investor@endo.com